THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Dr. Dan Riskin, CEO, VerantosVerantos provides turnkey solutions to implement high-validity studies by applying advanced technologies to deliver insights for pharmaceutical firms to use in collaboration with regulators, payers, and providers. It combines advanced data and technology into a secure platform to offer high-validity evidence.
Among the RWE firms, there are two axes of differentiations: Traditional versus advanced techniques and oncology versus non-oncology studies. Oncology studies tend to use advanced techniques including detailed information gathered from narrative records. Thousands of annotators pour through these records every day to enable oncology RWE studies that typically include hundreds of patients. On the other hand, in non-oncology fields such as heart disease and neuroscience, there is no good solution to run advanced RWE studies. These studies typically include thousands of patients, found from millions of patients. Each patient may have thousands of pages of medical records. It is simply not feasible to engage clinicians to review billions of pages of records per study. So, non-oncology RWE has been underserved. Where traditional firms use simple datasets, there are few offerings for non-oncology advanced RWE.
Verantos has addressed this need. By collaborating closely with health systems and applying modern forms of artificial intelligence, Verantos has been able to gain a comprehensive and accurate view of millions of patients. Verantos focuses on the medical sciences, with a specialization in cardiovascular medicine, neuroscience, immunology, and metabolic syndrome. “Our customers seek technological capabilities to run advanced RWE studies during clinical and commercial phases,” mentions Riskin, CEO, Verantos.
The clinical phase is the process of understanding the patient population and preparing for the product launch. In the commercial phase, firms look for high-validity studies to enable post-marketing commitments, market access, and clinical decision-making.
A maven in the RWE field, Verantos offers a boutique experience to its clients throughout pilots and clinical studies to ensure that all stakeholders are engaged with the process, and success criteria are met. Riskin recalls when a leading pharmaceutical firm was expanding its traditional RWE division to incorporate advanced RWE. The customer knew they needed to access EHRs and unstructured data to gain a clear picture of the patient, but they wanted to implement all this through a pilot study and learn the process. Verantos worked with the client, starting with a technology pilot stage to demonstrate high-accuracy, subsequently moving on to a series of clinical studies, understanding patient phenotypes, and performing claims and registry linkage to gain visibility into patient outcomes and resource utilization. After that, the client used these capabilities to enable Phase III efforts and product launch. They also extended to additional therapeutic areas within the enterprise.
In terms of technology use, many firms want high-validity studies. Thus, accuracy must be tested regardless of the technology applied. But, some technologies result in higher accuracy than others. For this reason, Verantos believes that AI, including natural language processing (NLP) and pattern recognition to support inference, is essential to achieve high-accuracy data extraction in healthcare. “In the studies we perform, data accuracy is unparalleled; greater than 85 percent compared to industry norms of 30 to 40 percent,” explains Riskin. “In terms of data provenance, every extracted element and the enriched portion of the patient record can be traced to each condition, medication, lab, and procedure.” The distinctive vision to employ validated AI earned Verantos funding from the National Institutes of Health, the National Science Foundation, and the Food and Drug Administration.
-
“Our customers seek technological capabilities to run advanced RWE studies during clinical and commercial phases,” mentions Riskin, CEO, Verantos.
A maven in the RWE field, Verantos offers a boutique experience to its clients throughout pilots and clinical studies to ensure that all stakeholders are engaged with the process, and success criteria are met. Riskin recalls when a leading pharmaceutical firm was expanding its traditional RWE division to incorporate advanced RWE. The customer knew they needed to access EHRs and unstructured data to gain a clear picture of the patient, but they wanted to implement all this through a pilot study and learn the process. Verantos worked with the client, starting with a technology pilot stage to demonstrate high-accuracy, subsequently moving on to a series of clinical studies, understanding patient phenotypes, and performing claims and registry linkage to gain visibility into patient outcomes and resource utilization. After that, the client used these capabilities to enable Phase III efforts and product launch. They also extended to additional therapeutic areas within the enterprise.
Verantos’ future endeavors are to continue in the advanced RWE field and offer the most rigorous, high-validity, and technology-enabled studies in the industry. “We aspire to demonstrate an approach to RWE that matches the rigor of randomized controlled trials, but provides additional insight to help tailor therapy and improve care,” ends Riskin.
Company
Verantos
Management
Dr. Dan Riskin, CEO, Verantos
Description
Verantos provides turnkey solutions to implement high-validity studies by applying advanced technologies to deliver insights for pharmaceutical firms to use in collaboration with regulators, payers, and providers. It combines advanced data and technology into a secure platform to offer high-validity evidence. Verantos provides the most rigorous and credible real-world evidence studies in the industry, using advanced technologies. Verantos focuses on the medical sciences, with a specialization in cardiovascular medicine, neuroscience, immunology, and metabolic syndrome. Verantos offers a boutique experience to its clients throughout the pilots and clinical studies to ensure that all stakeholders are engaged with the process, and success criteria are met
Verantos News
Verantos Announces Partnership with CuriMeta to Advance High-Validity, Real-World Evidence
The Verantos Research Network is a distributed collection of academic and community health systems, claims sources, and registries. Its focus on high-quality data ensures that customers have access to RWD with unparalleled richness and reliability.
"The Verantos Evidence Platform uses artificial intelligence (AI) to generate unique disease-specific insights. It is critical that AI models are trained using high-quality patient care data," said Anand Shroff, President of Verantos. "CuriMeta's participation will enable us to enhance our disease-specific Pragmatic Registries that are used to accelerate life sciences research."
CuriMeta's mission is to connect leading, mission-driven health systems and academic medical centers with life sciences organizations to pursue ground-breaking research and deliver new diagnostics and therapeutics, and the collaboration with the Verantos Research Network helps further those goals.
"Complex therapies necessitate providing more robust evidence and greater clinical value to achieve acceptance by regulators, providers, and patients," Davis Walp, CEO of CuriMeta, said. "Our partnership with Verantos will help connect patients with lifesaving therapies in the future."
The two companies will collaborate across therapeutic areas. CuriMeta's data will support a number of Verantos' current and planned disease-specific Pragmatic Registries.